DGAP-News: ABIVAX / Key word(s): Scientific publication
Abivax Publishes Review in Drug Discovery Today on Mechanism of Action and Transformative Potential of ABX464 as Therapy for Inflammatory Diseases
PARIS, January 5, 2021 - 7:00 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announced that the Company published an invited review in the renowned journal Drug Discovery Today on the "Specific and selective induction of miR-124 in immune cells by ABX464: a transformative therapy for inflammatory diseases".
Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, said: "Our recent publication in Drug Discovery Today once again demonstrates the unique mechanism of action and transformative potential of our lead drug candidate ABX464 to effectively and durably treat chronic inflammatory diseases. We are therefore very much looking forward to seeing the results of our ongoing clinical trials which are expected in Q2 2021, namely the Phase 2b trial in UC, the Phase 2a trial in rheumatoid arthritis as well as the Phase 2b/3 study in Covid-19 disease with the objective to prevent hyper-inflammation in high-risk patients. We are also keen to initiate the pivotal Phase 2b/3 clinical study in Crohn's disease in the course of this year. The review, describing the potent anti-inflammatory pathways of ABX464, also backs our assumption of ABX464's blockbuster potential across various chronic inflammatory diseases. Abivax will therefore continue to investigate possible additional indications in which the molecule could substantially improve the lives of patients in need of new, efficient and long-term effective therapeutic options."
In clinical studies for the treatment of ulcerative colitis, ABX464 is the first-in-class small molecule that has shown to induce and upregulate a specific microRNA, miR-124, in human immune cells leading to a robust and long-lasting anti-inflammatory effect in UC patients. The review summarizes the multiple effects of ABX464 in dampening inflammatory processes through the downregulation of several critical pro-inflammatory cytokines and cells, like TNFa, IL-6, MCP-1, IL-17 and Th17+ cells, emphasizing the potential of Abivax's lead drug candidate as an efficient and long-term effective therapy for the treatment of inflammatory diseases.
"By increasing the expression of miR-124 in the immune system cells, ABX464 inhibits the excessive inflammatory response that causes inflammatory diseases, such as ulcerative colitis. The scientific publication shows that miR-124 acts as an endogenous regulator of inflammation that limits the activation of the signalling pathways which are responsible for the expression of pro-inflammatory cytokines," explained Prof. Jamal Tazi, Ph.D., Vice President Research at Abivax. "This is the reason why ABX464 treats the root cause of inflammation at the molecular level, and consequently explains its efficacy in inducing and maintaining the clinical remission that we observed in Phase 2a clinical trials in ulcerative colitis patients along with a good safety and tolerability profile."
About ABX464's Mechanism of Action
About Abivax (www.abivax.com)
05.01.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.